Burnet N G, Bliss J M, Harmer C L
Sarcoma Unit Royal Marsden Hospital London UK.
Sarcoma. 1997;1(1):31-8. doi: 10.1080/13577149778452.
Purpose. Improvements in the systemic management of Ewing's sarcoma of bone over the last 20 years have led to a dramatic improvement in survival. The corollary is that treatment of the primary disease requires re-evaluation, since a significant number of patients still suffer local relapse.Patients. The effect of radiation dose on local control was reviewed in a series of 96 patients treated between 1967 and 1986. Seventy-four had no metastases at presentation (M0), 22 had metastases (M1). The 5-year survival of all patients was 28%, and of M0 patients alone 37%. Although these figures are poor by today's standards, they are consistent with published studies whose patients were enrolled during the same calendar period. Although most deaths occurred by 5 years, survival continued to fall beyond 10 years, which has implications for follow-up in future studies.Results. The local control (LC) rate at 5 years was 56% for all patients and for M0 patients analyzed separately. There was no difference in either LC or survival between the first and second decades of the study. Primary site was a significant determinant of survival and local control, with better outcome for limb tumours compared to pelvic primaries. Chemotherapy also had a major effect on LC. Radiotherapy improved the probability of LC. Omission of radiotherapy, or a dose <40 Gy, was ineffective. In the dose range 40-66 Gy, there was no evidence of a dose-response relationship.
目的。在过去20年中,骨尤文肉瘤全身治疗的改进使生存率得到了显著提高。相应地,由于仍有相当数量的患者出现局部复发,因此对原发性疾病的治疗需要重新评估。
患者。回顾了1967年至1986年间接受治疗的96例患者中放射剂量对局部控制的影响。74例初诊时无转移(M0),22例有转移(M1)。所有患者的5年生存率为28%,仅M0患者为37%。尽管按照如今的标准这些数字并不理想,但与同一时期登记入组患者的已发表研究结果一致。虽然大多数死亡发生在5年时,但生存率在10年后仍持续下降,这对未来研究的随访有影响。
结果。所有患者以及单独分析的M0患者5年时的局部控制(LC)率均为56%。研究的第一个十年和第二个十年在LC或生存率方面均无差异。原发部位是生存和局部控制的重要决定因素,与骨盆原发性肿瘤相比,肢体肿瘤的预后更好。化疗对LC也有重大影响。放疗提高了LC的可能性。省略放疗或剂量<40 Gy无效。在40 - 66 Gy的剂量范围内,没有证据表明存在剂量反应关系。